HIT Typ II in der operativen Medizin ... - Vascularcare.de

[122] Sheridan D, Carter C, Kelton JG: A diagnostic test for heparininducedthrombocytopenia. Blood 67 (1986) 27–30[123] Smythe MA, Warkentin TE, Stephens JL, Zakalik D, Mattson JC:Venous limb gangrene during overlapping therapy with warfarinand a direct thrombin inhibitor for immune heparin-inducedthrombocytopenia. Am J Hematol 71 (2002) 50–52[124] Stiekema JC, Van Griensven JM, Van Dinther TG, Cohen AF: Across-over comparison of the anti-clotting effects of three lowmolecular weight heparins and glycosaminoglycuronan. Br J ClinPharmacol 36 (1993) 51–56[125] Stratmann G, deSilva AM, Tseng EE, Hambleton J, Balea M,Romo AJ, Mann MJ, Achorn NL, Moskalik WF, Hoopes CW:Reversal of direct thrombin inhibition after cardiopulmonarybypass in a patient with heparin-induced thrombocytopenia.Anesth Analg 98 (2004) 1635–39[126] Swartz R, Pasko D, O'Toole J, Starmann B: Improving the deliveryof continuous renal replacement therapy using regional citrateanticoagulation. Clin Nephrol 61 (2004) 134–43[127] Vargas Hein O, Kox WJ, Spies C: Anticoagulation in continuousrenal replacement therapy. Contrib Nephrol 144 (2004) 308–16[128] Vargas Hein O, von Heymann C, Lipps M, Ziemer S, Ronco C,Neumayer HH, Morgera S, Welte M, Kox WJ, Spies C: Hirudinversus heparin for anticoagulation in continuous renal replacementtherapy. Intensive Care Med 27 (2001) 673–79[129] Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patientswith heparin-induced thrombocytopenia/thrombosis are specificfor platelet factor 4 complexed with heparin or bound to endothelialcells. J Clin Invest; 93 (1994) 81–88[130] Vun CM, Evans S, Chong BH: Cross-reactivity study of lowmolecular weight heparins and heparinoid in heparin-inducedthrombocytopenia. Thromb Res 81 (1996) 525–32[131] Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J:Biochemical and pharmacologic rationale for the development ofa synthetic heparin pentasaccharide. Thromb Res 86 (1997) 1–36[132] Walenga JM, Jeske WP, Prechel MM, Bakhos M: Newer insights onthe mechanism of heparin-induced thrombocytopenia. SeminThromb Hemost 30 (2004) 57–67[133] Warkentin TE, Chong BH, Greinacher A: Heparin-induced thrombocy-topenia:Towards consensus. Thromb Haemost 79 (1998) 1–7[134] Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI,Kelton JG: The pathogenesis of venous limb gangrene associatedwith heparin-induced thrombocytopenia. Ann Intern Med 127(1997) 804–12[135] Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia:recognition, treatment, and prevention: the Seventh ACCPConference on Antithrombotic and Thrombolytic Therapy. Chest.2004;126(3 Suppl):311S-337S[136] Warkentin TE, Kelton JG: A 14-year study of heparin-inducedthrombocytopenia. Am J Med 101 (1996) 502–7[137] Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopeniaand thrombosis. Ann Intern Med 135 (2001) 502-6[138] Warkentin TE, Kelton JG: Interaction of heparin with platelets,including heparin-induced thrombocytopenia. In: Low-Molecular-Weight Heparins in Prophylaxis and Therapy of ThromboembolicDiseases. Bounameaux H, ed. Marcel Dekker, New York (1994)75–127[139] Warkentin TE, Kelton JG: Temporal Aspects of Heparin-InducedThrombocytopenia. N Engl J Med 344 (2001) 1286–92[140] Warkentin TE: An overview of the heparin-induced thrombocytopeniasyndrome. Semin Thromb Hemost 30 (2004) 273–83[141] Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE: A comparisonof the efficacy and rate of response to oral and intravenousVitamin K in reversal of over-anticoagulation with warfarin. Br JHaematol 115 (2001) 145–49[142] Westphal K, Martens S, Strouhal U, Matheis G, Lindhoff-Last E,Wimmer-Greinecker G, Lischke V: Heparin-induced thrombocytopeniatype II: perioperative management using danaparoid in acoronary artery bypass patient with renal failure. ThoracCardiovasc Surg 45 (1997) 318–20[143] Wolzt M, Levi M, Sarich TC, Bostrom SL, Eriksson UG, Eriksson-Lepkowska M, Svensson M, Weitz JI, Elg M, Wahlander K: Effectof re-combinant factor VIIa on melagatran-induced inhibition ofthrombin generation and platelet activation in healthy volunteers.Thromb Haemost 91 (2004) 1090–96Anschrift des Verfassers:Dr. med. Christian von Heymann, DEAAKlinik für Anästhesiologie undoperative IntensivmedizinCharité – Universitätsmedizin BerlinCampus Charité MitteSchumannstraße 20–2110117 BerlinVASCULAR CARE 1/2005 VOL. 8 53